The CHMP has recommended approval of Pfizer’s adalimumab biosimilar (Amsparity) for treatment of certain inflammatory and autoimmune disorders in adults and children.
International Approvals …read more
The CHMP has recommended approval of Pfizer’s adalimumab biosimilar (Amsparity) for treatment of certain inflammatory and autoimmune disorders in adults and children.
International Approvals …read more